Physician profile
Jennifer Lanzer
NPI 1205152154
$16,069.73
in general payments reported to CMS, 2019-2025
28 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,632 · 2020: $1,223 · 2021: $1,737 · 2022: $3,400 · 2023: $3,564 · 2024: $864 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351 · Education: $1,500 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.42 |
| Education | $1,500.00 |
| Travel and Lodging | $226.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,100.84 | 2021-2025 | Interstim, Ligasure |
| Medtronic USA, INC. | $2,703.13 | 2019-2020 | |
| Boston Scientific Corporation | $2,140.74 | 2019-2025 | Axonics, Bulkamid, Solyx Sis System |
| Axonics, INC. | $1,795.16 | 2020-2024 | Axonics, Bulkamid |
| Intuitive Surgical, INC. | $1,743.45 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Astellas Pharma US INC | $1,040.87 | 2019-2024 | Myrbetriq, Veozah |
| Abbvie INC. | $712.22 | 2020-2025 | |
| Allergan, INC. | $478.39 | 2019-2022 | |
| Coloplast Corp | $383.74 | 2019-2024 | Speedicath, Altis |
| Pfizer INC. | $380.74 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $93.38 | 2023-2025 | Gemtesa, Myfembree |
| Aroa Biosurgery Incorporated | $77.42 | 2024 | |
| Coopersurgical, INC. | $64.81 | 2019-2025 | Paragard T 380a |
| Smith+Nephew, INC. | $57.00 | 2019-2025 | Grafix Pl, Stravix |
| Baxter Healthcare | $56.27 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $33.96 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $33.07 | 2025 | |
| Ethicon US, LLC | $20.92 | 2019 | |
| Therapeuticsmd, INC. | $20.41 | 2019 | |
| Millicent US INC | $17.86 | 2025 | Femlyv, Intrarosa |
| Mayne Pharma Commercial LLC | $17.32 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.46 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $15.43 | 2019 | |
| Currax Pharmaceuticals LLC | $15.12 | 2019 | |
| Sage Therapeutics, LLC | $14.19 | 2019 | |
| Laborie Medical Technologies Corp. | $13.80 | 2022 | |
| Hologic Sales and Service, LLC | $13.34 | 2019 | |
| Molnlycke Health Care US, LLC | $10.69 | 2024 | Mepilex Border Post-Op Ag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lanzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.